PE20151409A1 - Analogo de insulina novedoso y su uso - Google Patents

Analogo de insulina novedoso y su uso

Info

Publication number
PE20151409A1
PE20151409A1 PE2015001747A PE2015001747A PE20151409A1 PE 20151409 A1 PE20151409 A1 PE 20151409A1 PE 2015001747 A PE2015001747 A PE 2015001747A PE 2015001747 A PE2015001747 A PE 2015001747A PE 20151409 A1 PE20151409 A1 PE 20151409A1
Authority
PE
Peru
Prior art keywords
insulin
conjugate
insulin analogue
new insulin
reduced
Prior art date
Application number
PE2015001747A
Other languages
English (en)
Inventor
Sang Youn Hwang
Yong Ho Huh
Jin Young Kim
Sung Hee Hong
In Young Choi
Sung Youb Jung
Se Chang Kwon
Dae Jin Kim
Hyun Uk Kim
Myung Hyun Jang
Seung Su Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20151409A1 publication Critical patent/PE20151409A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invencion se refiere a un analogo de insulina que tiene un titulo de insulina reducido y una afinidad de union del receptor de insulina reducida en comparacion con la forma natural con el fin de incrementar la semivida de la insulina en sangre, un conjugado que se prepara enlazando el analogo de insulina y un vehiculo, una formulacion de accion prolongada que incluye el conjugado y un procedimiento para preparar el conjugado
PE2015001747A 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso PE20151409A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130020703 2013-02-26
KR20130082511 2013-07-12
KR20140006937 2014-01-20

Publications (1)

Publication Number Publication Date
PE20151409A1 true PE20151409A1 (es) 2015-10-07

Family

ID=51428522

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2015001747A PE20151409A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso
PE2019001804A PE20191481A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019001804A PE20191481A1 (es) 2013-02-26 2014-02-26 Analogo de insulina novedoso y su uso

Country Status (25)

Country Link
US (2) US20160008483A1 (es)
EP (2) EP3616727B1 (es)
JP (3) JP6552968B2 (es)
KR (2) KR20140106452A (es)
CN (2) CN104995206B (es)
AU (2) AU2014221531B2 (es)
BR (1) BR112015019985A2 (es)
CA (1) CA2901873C (es)
CL (1) CL2015002330A1 (es)
DK (1) DK2963056T3 (es)
ES (2) ES2868351T3 (es)
HK (1) HK1211944A1 (es)
IL (1) IL240717B (es)
MX (1) MX366400B (es)
MY (1) MY186990A (es)
PE (2) PE20151409A1 (es)
PH (1) PH12015501814A1 (es)
PT (1) PT2963056T (es)
RU (1) RU2676729C2 (es)
SA (2) SA518400491B1 (es)
SG (2) SG11201506095TA (es)
TW (3) TWI621626B (es)
UA (1) UA119533C2 (es)
WO (1) WO2014133324A1 (es)
ZA (1) ZA201507104B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
PE20151409A1 (es) * 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
CN116987172A (zh) 2014-01-20 2023-11-03 韩美药品株式会社 长效胰岛素及其用途
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
US10894089B2 (en) * 2015-02-17 2021-01-19 Hanmi Pharm. Co., Ltd. Long-acting insulin or insulin analogue conjugate
EP3325496B1 (en) 2015-07-24 2024-02-07 Hanmi Pharm. Co., Ltd. Method of preparing physiologically active polypeptide conjugate
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017052305A1 (en) * 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Method of insulin production
TWI774694B (zh) * 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
EP3549950A4 (en) * 2016-12-05 2020-08-19 Hanmi Pharm. Co., Ltd. CONJUGATE WITH MITIGATED IMMUNE RESPONSE
DK3551209T3 (da) 2016-12-09 2021-08-23 Akston Biosciences Corp Insulin-fc-fusioner og fremgangsmåder til anvendelse
CN110545849A (zh) 2017-02-03 2019-12-06 韩美药品株式会社 具有增加的持续性的生理活性物质的缀合物及其应用
CN110545852B (zh) 2017-02-07 2023-05-26 韩美药品株式会社 非肽聚合物接头化合物、包含该接头化合物的缀合物及制备该接头化合物和缀合物的方法
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
CA3054899A1 (en) * 2017-03-23 2018-09-27 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
WO2019066609A1 (ko) 2017-09-29 2019-04-04 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
LT3892628T (lt) 2018-06-29 2022-12-12 Akston Biosciences Corporation Itin ilgai veikiantys insulino-fc sulieti baltymai ir naudojimo būdai
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
TW202039438A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 胰島素接合物
AU2019405389A1 (en) 2018-12-21 2021-06-24 Hanmi Pharm. Co., Ltd. Pharmaceutical composition containing insulin and glucagon
CN113453703A (zh) 2018-12-21 2021-09-28 韩美药品株式会社 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
JP2022542301A (ja) * 2019-07-31 2022-09-30 イーライ リリー アンド カンパニー リラキシン類似体およびその使用方法
US11352407B2 (en) * 2019-12-19 2022-06-07 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR102545250B1 (ko) * 2020-03-31 2023-06-21 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그
EP4248983A3 (en) 2020-04-10 2024-01-24 Akston Biosciences Corporation Antigen specific immunotherapy for covid-19 fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
EP4230216A1 (en) * 2020-07-24 2023-08-23 Jiangsu Gensciences Inc. Insulin-fc fusion protein and application thereof
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
JPWO2023013638A1 (es) * 2021-08-02 2023-02-09
CN117881691A (zh) * 2021-08-02 2024-04-12 丝芭博株式会社 多孔质体及其制造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2008169195A (ja) * 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP5688969B2 (ja) * 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
EP2376520B1 (en) * 2008-12-19 2014-02-12 Indiana University Research&Technology Corporation Insulin analogs
US20120184488A1 (en) * 2009-09-01 2012-07-19 Case Western Reserve University Insulin analogues of enhanced receptor-binding specificity
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
KR101324828B1 (ko) * 2010-06-08 2013-11-01 한미사이언스 주식회사 면역글로불린 단편을 이용한 단쇄 인슐린 아날로그 약물 결합체
AU2011282988A1 (en) * 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PE20151409A1 (es) * 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso

Also Published As

Publication number Publication date
SA515360933B1 (ar) 2018-12-23
ES2868351T3 (es) 2021-10-21
BR112015019985A2 (pt) 2017-08-29
CA2901873C (en) 2022-05-03
MY186990A (en) 2021-08-26
PT2963056T (pt) 2020-02-19
EP3616727B1 (en) 2021-03-31
AU2018267648B2 (en) 2020-04-16
PH12015501814B1 (en) 2015-12-07
CN104995206B (zh) 2022-04-12
IL240717B (en) 2020-05-31
ES2770776T3 (es) 2020-07-03
CN104995206A (zh) 2015-10-21
NZ710882A (en) 2021-01-29
CL2015002330A1 (es) 2015-12-28
TW201520224A (zh) 2015-06-01
EP2963056B1 (en) 2019-11-13
KR102413691B1 (ko) 2022-06-28
US20180256731A1 (en) 2018-09-13
SG10201907106VA (en) 2019-09-27
CN114989289A (zh) 2022-09-02
AU2014221531A1 (en) 2015-08-27
JP2019187440A (ja) 2019-10-31
US20160008483A1 (en) 2016-01-14
RU2676729C2 (ru) 2019-01-10
WO2014133324A1 (ko) 2014-09-04
TW201920243A (zh) 2019-06-01
SG11201506095TA (en) 2015-09-29
SA518400491B1 (ar) 2022-04-07
JP2021193089A (ja) 2021-12-23
TWI708782B (zh) 2020-11-01
NZ751062A (en) 2021-04-30
KR20210109491A (ko) 2021-09-06
UA119533C2 (uk) 2019-07-10
CA2901873A1 (en) 2014-09-04
PE20191481A1 (es) 2019-10-18
EP2963056A4 (en) 2017-06-07
DK2963056T3 (da) 2020-02-17
AU2014221531B2 (en) 2018-08-23
ZA201507104B (en) 2019-04-24
EP3616727A1 (en) 2020-03-04
TWI755579B (zh) 2022-02-21
MX2015010471A (es) 2016-04-25
EP2963056A1 (en) 2016-01-06
PH12015501814A1 (en) 2015-12-07
RU2015138536A (ru) 2017-04-03
TW201817741A (zh) 2018-05-16
IL240717A0 (en) 2015-10-29
KR20140106452A (ko) 2014-09-03
HK1211944A1 (en) 2016-06-03
MX366400B (es) 2019-07-08
JP6552968B2 (ja) 2019-07-31
JP2016510003A (ja) 2016-04-04
TWI621626B (zh) 2018-04-21
AU2018267648A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
PE20151409A1 (es) Analogo de insulina novedoso y su uso
AR094904A1 (es) Análogos de insulina y su uso
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CL2017002110A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos (divisional solicitud 201502357)
CL2016000468A1 (es) Conjugados anti-dll3 (ligando3 tipo delta) manipulados y métodos de uso.
DOP2016000145A (es) Reguladores de nrf2
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201890942A1 (ru) Мультивалентные вакцины с синтетическими наноносителями
BR112016008736A2 (pt) formulação estável de insulina glulisina
BR112015004515A2 (pt) composição imunogênica
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
EA201591451A1 (ru) Модуляторы flap
CL2012003458A1 (es) Vector que comprende un polipeptido antigénico de campylobacter; composicion farmacéutica que comprende dicho vector; uso del vector para mejorar respuesta inmune del sujeto al polipéptido antigénico.
ECSP15050386A (es) FORMULACIONES ALTERNATIVAS PARA POLIPÉPTIDOS DE FUSIÓN TNFR: Fc
PH12016500924A1 (en) Anti-cancer agents and preparation thereof
UY35651A (es) Pirazolpiridinas sustituidas
CO7151478A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
BR112015032388A2 (pt) métodos e composições para as vacinas contra o vírus da dengue
ES2656474T3 (es) Osteopontina láctea de origen mamífero para potenciar la capacidad de respuesta inmune
ES2403549R1 (es) Co-cristales de agomelatina con formadores de co-cristales

Legal Events

Date Code Title Description
FG Grant, registration